161 related articles for article (PubMed ID: 33043062)
21. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
[TBL] [Abstract][Full Text] [Related]
22. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
[TBL] [Abstract][Full Text] [Related]
23. Use of on-therapy ctDNA monitoring in a patient with
Yeung V; Kim C; Kiedrowski LA; Liu SV; Reuss JE
Transl Lung Cancer Res; 2022 Jan; 11(1):111-116. PubMed ID: 35242632
[TBL] [Abstract][Full Text] [Related]
24. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
[TBL] [Abstract][Full Text] [Related]
25. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
26. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
Front Oncol; 2021; 11():751106. PubMed ID: 35273907
[TBL] [Abstract][Full Text] [Related]
27. Concordance of Genomic Profiles in Matched Tissue and Plasma Samples From Chinese Patients With Lung Cancer.
He Y; Guo W; Xu M; Huang J; Zhang X; Su H; Hong D; Liu Q
Clin Med Insights Oncol; 2022; 16():11795549221116834. PubMed ID: 36310733
[TBL] [Abstract][Full Text] [Related]
28. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
29. Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.
Xie F; Zheng X; Mao X; Zhao R; Ye J; Zhang Y; Sun J
Ann Thorac Surg; 2019 Jul; 108(1):219-226. PubMed ID: 30885850
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
31. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
Cui S; Zhang W; Xiong L; Pan F; Niu Y; Chu T; Wang H; Zhao Y; Jiang L
Oncotarget; 2017 Jan; 8(2):2771-2780. PubMed ID: 27926526
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.
Creemers A; Krausz S; Strijker M; van der Wel MJ; Soer EC; Reinten RJ; Besselink MG; Wilmink JW; van de Vijver MJ; van Noesel CJM; Verheij J; Meijer SL; Dijk F; Bijlsma MF; van Oijen MGH; van Laarhoven HWM
Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):394-403. PubMed ID: 28801248
[TBL] [Abstract][Full Text] [Related]
33. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
34. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
35. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
36. Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAM
Garcia J; Gauthier A; Lescuyer G; Barthelemy D; Geiguer F; Balandier J; Edelstein DL; Jones FS; Holtrup F; Duruisseau M; Grolleau E; Rodriguez-Lafrasse C; Merle P; Couraud S; Payen L
Mol Diagn Ther; 2021 Mar; 25(2):239-250. PubMed ID: 33660188
[TBL] [Abstract][Full Text] [Related]
37. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
38. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K
Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374
[TBL] [Abstract][Full Text] [Related]
39. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
40. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
Zugazagoitia J; Rueda D; Carrizo N; Enguita AB; Gómez-Sánchez D; Díaz-Serrano A; Jiménez E; Mérida A; Calero R; Lujan R; De Miguel E; Gámez P; Díaz-Hellín V; Nuñez JA; Iglesias L; Ferrer I; Paz-Ares L; Ponce-Aix S
Clin Lung Cancer; 2018 Jan; 19(1):65-73.e7. PubMed ID: 28780976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]